One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one aralkyl ligand. In certain embodiments, an aralkyl ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, an aralkyl ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage. In a preferred embodiment, the aralkyl ligand is naproxen or ibuprofen. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one aralkyl ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage. In a preferred embodiment, the aralkyl ligand is naproxen or ibuprofen. The aralkyl ligand improves the pharmacokinetic properties of the oligonucleotide.
本发明的一个方面涉及含有至少一种芳基烃基
配体的双链寡核苷酸。在某些实施例中,芳基烃基
配体仅与组成双链寡核苷酸的两个寡核苷酸链中的一个结合。在某些实施例中,芳基烃基
配体结合到组成双链寡核苷酸的两个寡核苷酸链中的两个。在某些实施例中,寡核苷酸链包含至少一个修饰的糖基团。在某些实施例中,寡核苷酸中的至少一个
磷酸酯键已被替换为
磷酸硫酯键。在一个优选实施例中,芳基烃基
配体是
萘普生或
布洛芬。本发明的另一个方面涉及含有至少一种芳基烃基
配体的单链寡核苷酸。在某些实施例中,寡核苷酸包含至少一个修饰的糖基团。在某些实施例中,寡核苷酸中的至少一个
磷酸酯键已被替换为
磷酸硫酯键。在一个优选实施例中,芳基烃基
配体是
萘普生或
布洛芬。芳基烃基
配体改善了寡核苷酸的药代动力学特性。